180 related articles for article (PubMed ID: 23180012)
1. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.
Xishan Z; Xinna Z; Baoxin H; Jun R
Cancer Immunol Immunother; 2013 Apr; 62(4):689-703. PubMed ID: 23180012
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
Li Q; Wu Y; Fang S; Wang L; Qi H; Zhang Y; Zhang J; Li W
Cancer Gene Ther; 2015 May; 22(5):227-37. PubMed ID: 25837664
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
[TBL] [Abstract][Full Text] [Related]
4. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.
Xishan Z; Guangyu A; Yuguang S; Hongmei Z
J Exp Clin Cancer Res; 2011 May; 30(1):47. PubMed ID: 21535879
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts.
Zhu X; Wang L; Zhang B; Li J; Dou X; Zhao RC
J Biochem; 2011 Apr; 149(4):405-14. PubMed ID: 21288887
[TBL] [Abstract][Full Text] [Related]
6. Molecular biological characteristics of the recruitment of hematopoietic stem cells from bone marrow niche in chronic myeloid leukemia.
Zhu B; Zhang J; Chen J; Li C; Wang X
Int J Clin Exp Pathol; 2015; 8(10):12595-607. PubMed ID: 26722450
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
8. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
9. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
[TBL] [Abstract][Full Text] [Related]
10. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
11. HER-2-induced PI3K signaling pathway was involved in the pathogenesis of gastric cancer.
Fu YF; Gui R; Liu J
Cancer Gene Ther; 2015 Apr; 22(3):145-53. PubMed ID: 25613482
[TBL] [Abstract][Full Text] [Related]
12. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
13. Tumour promoting functions of TGF-β in CML-initiating cells.
Miyazono K
J Biochem; 2012 Nov; 152(5):383-5. PubMed ID: 22989931
[TBL] [Abstract][Full Text] [Related]
14. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Huang FF; Zhang L; Wu DS; Yuan XY; Yu YH; Zhao XL; Chen FP; Zeng H
PLoS One; 2014; 9(3):e88298. PubMed ID: 24603487
[TBL] [Abstract][Full Text] [Related]
15. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
16. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
19. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.
Fang B; Zheng C; Liao L; Han Q; Sun Z; Jiang X; Zhao RC
Blood; 2005 Apr; 105(7):2733-40. PubMed ID: 15591120
[TBL] [Abstract][Full Text] [Related]
20. Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia.
Xishan Z; Xu Z; Lawei Y; Gang L
Clin Lab; 2012; 58(7-8):607-13. PubMed ID: 22997961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
